Fibrosis: Cross Organ Pathology and Pathways to Clinical Development (K4)
February 2-5, 2026
| Fairmont Banff Springs, Banff, AB, Canada
Florian Rieder, Tatiana Kisseleva and Marco Prunotto
Scholarship Deadline: Oct. 8, 2025 | Abstract Deadline: Jan. 13, 2026 | Early Registration Deadline: Dec. 4, 2025
| 4:00–8:00 PM |
Registration |
Van Horne Foyer |
| 6:00–8:00 PM |
Welcome Mixer |
Van Horne Foyer |
Tuesday, February 3, 2026
| 7:00–8:00 AM |
Breakfast |
President's Hall |
| 8:00–9:00 AM |
Welcome and Keynote Address (Joint) |
Van Horne A/B |
| |
Thomas A Wynn, Pfizer
The Future of Anti-Fibrotic Therapy: Scar Macs and Beyond |
|
| 9:00–11:15 AM |
From Fibroblasts to Fibrosis, and Back Again (Joint) |
Van Horne A/B |
| |
Boris Hinz, St. Michael's Hospital and University of Toronto
To Push or Pull? How the Mechanical Environment Affects Stromal Activation |
|
| |
Sheila A. Stewart, Washington University School of Medicine
Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy |
|
| |
Michael B. Brenner, Harvard Medical School
Notch and Wnt Signaling in Inflammatory Fibroblast-Mediated Pathology |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
Van Horne Foyer |
| 11:15–1:00 PM |
Poster Setup |
Van Horne C |
| 11:15–2:30 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Van Horne C |
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
Van Horne A |
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
Van Horne Foyer |
| 5:00–7:00 PM |
Mechanisms of the Extracellular Matrix Environment Driving Disease |
Van Horne A |
| |
Rachel Lennon, University of Manchester
The Matrisome in Disease Pathology |
|
| |
Natalie J. Torok, Stanford University
Viscoelasticity Promoting Cancer Progression |
|
| |
Detlef Schuppan, Beth Israel Deaconess Medical Center
Targeting the ECM to Treat Liver Fibrosis and Liver Cancer |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
President's Hall |
| 7:30–10:00 PM |
Posters |
Van Horne C |
Wednesday, February 4, 2026
| 7:00–8:00 AM |
Breakfast |
President's Hall |
| 8:00–10:30 AM |
Fibroblast Heterogenity across Organs: A Critical Basis for Discovery and Therapy Translation |
Van Horne A |
| |
Suzanne Devkota, Cedars-Sinai Medical Center
Microbiome Influence on Adipose Tissue Fibrosis |
|
| |
Florian Rieder, Cleveland Clinic
Fibroblast interactions in Intestinal Fibrosis |
|
| |
Stefanie Dimmeler, Institute of Cardiovascular Regeneration
Persistent Fibroblast Activation in the Hypertrophic Human Heart |
|
| |
Dean Sheppard, University of California, San Francisco
The Alveolar Fibroblast Lineage in Lung Inflammation and Fibrosis |
|
| 9:00–9:20 AM |
Coffee Break |
Van Horne Foyer |
| 10:30–11:00 AM |
Panel Discussion 1: Fibroblast Heterogeneity Across Organs |
Van Horne A |
| 11:00–1:00 PM |
Poster Setup |
Van Horne C |
| 11:00–3:30 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Van Horne C |
| 3:30–4:30 PM |
Career Roundtable (Joint) |
Van Horne B |
| 4:30–5:00 PM |
Coffee Available |
Van Horne Foyer |
| 5:00–7:00 PM |
Mechanisms that Drive the Progression and Regression of Fibrosis |
Van Horne A |
| |
Scott L Friedman, Icahn School of Medicine at Mount Sinai
Genetics linked with Fibrosis: Commonalities and Differences across Organs |
|
| |
Pilar Alcaide, Tufts University School of Medicine
The Crossroad of Inflammation and Fibrosis: Fibroblast and Immune Cell Interactions |
|
| |
Tatiana Kisseleva, University of California, San Diego
Mechanisms of Regression of Liver Fibrosis |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
President's Hall |
| 7:30–10:00 PM |
Posters |
Van Horne C |
Thursday, February 5, 2026
| 7:00–8:00 AM |
Breakfast |
President's Hall |
| 8:00–10:30 AM |
Drug Development Pathways for Fibrosis – From Mechanisms to Medicine |
Van Horne A |
| |
David Brenner, Sanford Burnham Prebys
Preclinical Models of Fibrosis: Are we able to Predict Therapy Response |
|
| |
Marco Prunotto, Medicxi
Drug Development Pathways for Fibrotic Diseases: Lessons Learned |
|
| |
Andrea Sáez, Agomab Therapeutics
Local Delivery ALK5 Inhibitors to Treat Lung and Intestinal Fibrosis |
|
| |
Shannon J Turley, Genentech, Inc.
Elucidating Regulators of Pathogenic Stroma in Fibrotic and Inflammatory Diseases |
|
| 9:00–9:20 AM |
Coffee Break |
Van Horne Foyer |
| 10:30–11:00 AM |
Panel Discussion 2: Preclincial Evaluation and Clincial Development in Fibrotic Diseases |
Van Horne A |
| 11:00–2:30 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
Van Horne A |
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
Van Horne Foyer |
| 5:00–6:45 PM |
Therapeutic Modulation of Stromal Cell Function (Joint) |
Van Horne A/B |
| |
Viviana Cremasco, Novartis Biomedical Research
TGFb Neutralization and Tumor Stroma Modulation: From Bench to Bed |
|
| |
Yuval Rinkevich, Helmholtz Zentrum München, GmbH
Regenerative Medicine and Tissue Repair |
|
| |
Burkhard Ludewig, Kantonsspital St. Gallen
Immunomodulation of Myocardial Fibrosis |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Joint) |
Van Horne A/B |
| 7:00–8:00 PM |
Social Hour with Dinner |
President's Hall |
| 8:00–11:00 PM |
Entertainment |
|
